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M a n u s c r i p t 6 Sows of both herds were vaccinated for Aujeszky's disease (3 times/year), porcine 118 parvovirus and erysipelas (both at mid-lactation). Piglets were vaccinated to Aujeszky's disease 119 according to the National Control Program. 120 121
Experimental design 122
This study was a double-blind, randomised, controlled field trial performed according to the 123 principles of "Good Clinical Practice" and included 818 piglets (males and females). The day 124 before the inclusion, piglets were identified, double ear-tagged and assigned to the two treatment 125 groups [nonvaccinated/placebo (group A) and PCV2-vaccinated (group B)] as they came to hand 126 sequentially (A -B -A -B -A -B… etc.). The sequential allocation was continued over the 127 litters. The identification of the sow and the date of birth of the piglets were recorded. 128
At inclusion (weaning day, 21 ± 3 days of age), vaccinated animals (group B) received one 129 dose of a commercial PCV2a-based subunit vaccine (Porcilis PCV ® , Intervet/Schering-Plough 130
Animal Health, Boxmeer, The Netherlands) containing the PCV2 capsid (Cap) protein expressed in 131 a baculovirus system suspended in an α-tocopherol + liquid paraffin -based adjuvant administered 132 intramuscularly (2 mL) in the right neck muscle according to the recommendation of the 133 manufacturer. The same amount of adjuvant was injected in the same anatomic location in control 134 nonvaccinated pigs (group A). The administration of vaccine and placebo was performed using a 135 double-blind fashion system for both farms. Animals of both groups were injected at weaning and 136 moved to the nursery units. Table 1 lists the details of the study animals at the time of inclusion. 137
After weaning, pigs from both treatment groups were kept in mixed groups until the end of 138 the trial, when animals were sent to the slaughterhouse (at approximately 9 months of age). 139
Treatments, housing, husbandry, and feeding were conformed to the European Union Guidelines 140 and identical for both experimental groups at each farm. At each accommodation change, pigs were 141 commingled according to usual farm procedures.
A c c e p t e d M a n u s c r i p t 8 The objective of the pathologic studies was to establish the PMWS diagnosis in all pigs from 167 both farms that died, those needing euthanasia, and runts during the entire study period. These pigs 168 underwent gross pathologic examination and histopathology within 24 hours. Samples from 169 inguinal, mesenteric and mediastinic lymph nodes were removed from necropsied pigs and fixed in 170 10% buffered formalin. Fixed samples were processed for routine histopathology and 5-µm thick 171 sections were stained with hematoxylin and eosin to be examined for lesions compatible with 172 PMWS. The diagnosis of PMWS was made when all three criteria of the accepted international 173 individual case definition for the disease (clinical signs, mainly wasting, moderate-to-severe 174 lymphoid lesions, moderate-to-high amounts of PCV2 in those lesions) were present. The amount 175 of PCV2 in tissue samples was also assessed by real-time quantitative PCR (qPCR) using the 176 methods reported by Olvera and colleagues (2004) . 177
Immunohistochemistry for detection of PCV2-specific antigen was performed on formalin-178 fixed and paraffin-embedded sections of inguinal, mediastinal, and mesenteric lymph nodes using a 179 rabbit polyclonal antiserum (Sorden, 2000) . PCV2 antigen scoring was done by a pathologist in a 180 blinded manner using the score range in accordance with Opriessnig and coworkers (2004) . 181 The anti-PCV2 antibody titres in sera were determined using a blocking enzyme-linked 195 immunosorbent assay (ELISA). The wells of microtitre plates were coated overnight at 2-8C with 196 baculovirus-expressed PCV2 ORF2 antigen. Subsequently, the plates were washed and blocked 197 with casein buffer at 37C for 1 h. After washing, serial 4-fold dilutions of the test sera were added. 198
An internal standard serum and a positive and negative standard serum were run in parallel on each 199 plate. The sera were incubated for 1 h at 37C and the plates were then washed before the addition 200 of a PCV2-specific biotinylated monoclonal antibody (mAb). After 1 h incubation at 37C, plates 201 were washed again and incubated for 45 min at 37C with avidin-labeled horseradish peroxidase 202 (APO; DAKO A/S, Glostrup -Denmark). After washing, a 3,3′,5,5′-tetramethylbenzidine (TMB) 203 substrate solution was added and incubated for 15 min at room temperature. The reaction was 204 stopped by the addition of 4N sulphuric acid and the extinction was read in a photometer fitted with 205 a 450-nm filter (Titertek Multiscan Plus MK 11 -Titertek Instruments Inc., Huntsville, AL -USA) 206 within 15 min after the reaction was stopped. The raw data were processed and titres were 207 calculated using the Multi-calc program with a cut-off extinction value set at 50% blocking. The 208 cut-off extinction was calculated from the positive and negative standard serum and titres were 209 expressed as log 2 . 210 211
Detection of antibody titres to other infections 212
The presence of antibodies to PRRSV and sample/positive (S/P) ratio were determined using 213 
Statistical analysis 245
To estimate the effect of vaccination on the probability of a pig of becoming viremic, a 246 mixed effect logistic regression model was fitted to take into account the non-independence of the 247 repeated measures on the same subjects and the effect of the sow (litter effect). These two variables 248 were treated as "random effects" in the model, whereas the effect of the farm (two levels), sex, 249 time, and treatment and their interactions were considered as "fixed effects". The effect of the time 250 × treatment interaction was highly significant (P = 0.0146), indicating that these results are not 251 attributable to chance alone. The package "lme4" was used (Bates and Sarkar, 2007; lme4: linear 252 mixed-effects models using S4 classes, R package version 0.999375-32). 253
To estimate the effect of vaccination on the probability of a pig suffering from PCVD and 254 being lost, considering the competing risks of dying or being lost from other causes, a stratified Cox 255 proportional hazard model was fitted, according to Putter and coworkers (2007) and Therneau and 256 Grambsch (2000) . The model accounted also for the "cluster" effect of the sow ("litter effect") 257 because piglets from the same litter are expected to have similar clinical histories. 258
The effect of the vaccination on weight gain was evaluated within a mixed effects model, 259
given the hierarchical structure of the experiment (Pinheiro and Bates, 2000) . Vaccine efficacy was 260 measured by the proportion of cases that it prevented, comparing disease outcome in the treated 261 versus control groups. Efficacy was presented here as one-risk ratio (the so-called preventiveM a n u s c r i p t 12 fraction), which gives the risk in the vaccinated group as a proportion of the risk in the control 263 group (Kirkwood et al., 2003) . 264
Humoral and cellular immunity, determined as titres of anti-PCV2 antibodies and frequencies of 265 IFN-γ SC respectively, were statistically evaluated by using ANOVA (analysis of variance) and 266
Dunnett's test in order to higlight differences between treatment groups and changes over time 267 within the same group throughout the experiment. 268 Dead pigs, animals needing euthanasia, and runt non-marketable pigs (lost pigs) underwent 280 pathologic and virologic investigations to be categorised as PMWS and non-PMWS using the 281 recognised diagnostic criteria. The mortality rates in both groups were comparable before the onset 282 of viremia and all dead animals were not affected by PMWS. 283
At 15-16 weeks of age and onward in both herds, mortality was associated with PCR 284 positivity to PCV2 and with macroscopic and microscopic lesions referred to as PMWS using the 285 pathologic criteria. The details of the occurrence of mortality categorised as PMWS or non-PMWS 286 on a weekly basis at both farms are shown in Figure 2 .M a n u s c r i p t 13 Among the animals that had to be euthanised or removed because they were runts, after the 288 onset of PCV2 viremia they were removed from the study because of wasting (15 vs. 0 pigs; 289 placebo/control vs. vaccinated), growth retardation (12 vs. 3 pigs, respectively), locomotory 290 disorders (4 vs. 5 pigs, respectively), and intestinal torsions (1 vs. 2, respectively). 291
Before the onset of viremia, total losses were 7.3% and 7.8% and after PCV2 viremia 9.02% 292 and 0.2%, respectively, in the placebo/control and vaccinated groups. Overall, considering both 293 herds for the study duration, total losses (dead, euthanised, and runts) were 16.03% and 8.0% in the 294 placebo/control and vaccinated groups, respectively. The estimated hazard ratio for losses related to 295 PMWS in group B (vaccinated animals) compared with group A (placebo/control) was 0.082 296 (CI 95% : 0.030-0.229; P < 0.0001; Figure 3 ). Under the conditions of this study, according to a 297 stratified Cox proportional hazard model accounting for the non-independence of repeated 298 measurement of the same subject and the effect of the sow (litter effect) and for the competing risks 299 of dying from other causes, the probability of a pig vaccinated with a single dose of the test vaccine 300 at 3 weeks of age suffering from PCVD/PMWS was 12 times less than an unvaccinated control pig. 301
The overall efficacy of the vaccine administered, expressed as preventive fraction was 0.918 (CI 95% : 302 0.771-0.970). The preventive fraction represents and provides the proportion of cases that can be 303 prevented with vaccination compared to the unvaccinated population. 304 305 3.2. ADWG and carcass weight at slaughterhouseM a n u s c r i p t
14
The ADWG is considered a parameter for measuring the effect of PMWS either in acute or 307 in subclinical cases. Table 2 shows the ADWG in vaccinated and placebo/control animals for the 308 intervals among the three different weighing time points. The ADWG in the first time period (3-12 309 weeks of age) was not significantly different. Differences in the ADWG between the treatment 310 groups were observed during the subsequent time period (12-26 weeks), when the vaccinated 311 animals had 70 g/day higher weight gain than placebo/control animals (P < 0.001). Moreover, the 312 proportion of animals whose body weight was at least 25% lower than the mean body weight of the 313 respective treatment group at 26 weeks of age was 6.5% and 2.6% in placebo/control and 314 vaccinated groups, respectively. 315
Carcass weights in pigs from farm 2 were recorded at the slaughterhouse, as shown in Table  316 2. In vaccinated animals, the average carcass weight was 4.5 kg higher than in placebo/controls (P < 317 0.012). 318 319
PCV2 viremia 320
The course of PCV2 viremia at both farms is shown in Figure 4 . A sudden onset of viremia 321 was observed at 16-17 weeks of age at both farms. In farm 1, peak levels of 95-100% of PCR-322 positive blood samples from placebo/control animals were reached when animals were 20-22 weeks 323 old. A decline of PCR positivity was detected at 26 weeks. The majority of samples with high viral 324 loads (>10 6 DNA copies/mL serum) were observed at 19-22 weeks of age (Figure 4a ), and 70% of 325 the animals had at least one blood sample with a viral load >10 7 DNA copies/mL. Conversely, in 326 the vaccinated group, the proportion of viremic pigs was significantly lower compared to the 327 placebo/control group; between weeks 19 and 22 of age, 40% of the animals were viremic, with a 328 viral load never >10 6 DNA copies/mL serum (Figure 4b ). At farm 2, the peak of viremia was 329 observed at 18-20 weeks of age with 95% PCR-positive pigs; pigs with a high viral load ranged 330 from 55% to 60% (Figure 4c ). Viral burden >10 7 DNA copies/mL was detected in 42% of blood 331 M a n u s c r i p t 15 samples from the controls. In the vaccinated group only one blood sample was PCR positive at 18 332 weeks of age, with a low viral burden (<10 6 DNA copies/mL; Figure 4d ). 333
The present data clearly indicate that vaccination against PCV2 induced a statistically 334 significant reduction in the proportion of viremic animals and also of the viral load in the blood for 335 both farms in this study (P < 0.001). 336 337 3.4. Serology 338
Serologic response to PCV2 vaccination and infection 339
The course of serology for PCV2 in both farms is shown in Figure 5 . At inclusion 340 (vaccination day), pigs of both groups had comparable levels of ELISA antibodies due to residual 341 maternally derived antibodies (MDA) of 5.95 and 6.69 log 2 in placebo/control and vaccinated 342 animals, respectively. The difference was not statistically significant. After vaccination, in 343 placebo/control animals, antibody titres progressively declined, whereas a significant increase was 344 observed in vaccinated pigs so that, starting at 2 weeks PV, the differences between the two groups 345 were statistically significant. Animals in the vaccinated groups showed a continuous increase of 346 total antibody titres, reaching a peak of ELISA antibodies at 6-9 weeks PV, with an average 347 geometric mean ranging from 12 to 13 log 2 . From this time point on, the levels of total antibodies in 348 vaccinated groups slightly decreased even if never below a geometric mean of 6 log 2 . At the last 349 time point of blood sampling before the onset of viremia, the geometric mean of total antibodies in 350 the placebo/control animals were under the cut-off for positivity (set at 2 log 2 ) in sera of pigs from 351 farm 1 and a little over the limit (3.4 log 2 ) in pigs from farm 2. 352
In approximately 10% of the sampled population, the antibody titres at inclusion were 353 higher than 8 log 2. In vaccinated animals these titres showed neither an increase as a consequence of 354 vaccination nor a decline but mantained a steady course over time. In the placebo/control group, theM a n u s c r i p t 16 decline of maternally derived antibodies in animals with a titre higher than 8 log 2 reached low levels 356 within 10 weeks approximately (data not shown). 357
In both farms, after the onset of PCV2 viremia, seroconversion occurred within 2-3 weeks in 358 placebo/control or vaccinated groups so that at 20-22 weeks of age the antibody levels in both 359 groups were comparable (11-12 log 2 ). The geometric mean antibody titres of vaccinated animals at 360 26 and 35 weeks of age were lower than in placebo/control pigs because of a continuing increase of 361 antibodies in the latter group of animals. At the last sampling of this trial at 35 weeks of age, total 362 ELISA antibodies were above the titre of 10 log 2 in both treatment groups. 363 364
Serologic response to other infections 365 Serologic investigations performed to monitor the most frequently occurring infections in 366 the herds (PRRSV and M. hyopneumoniae) found that the prevalence of PRRSV infection was 367
100% at 12 weeks of age in pigs from farm 1 concomitantly with M. hyopneumoniae 368 seroconversion. For this latter antigen, seroprevalence continued to increase in the subsequent 369
period. 370
At farm 2, at 12 weeks of age, pigs of both groups were positive (100%) for PRRSV and 371 still negative for M. hyopneumoniae. Seroconversion to M. hyopneumoniae started to be detected 372 after 15 weeks of age (data not shown). 373
In both farms, low titres of antibodies at HI to Swine Influenza Virus were detected in some 374 samples and were inconclusive. 375 376
Cell-mediated immune response to PCV2-vaccination and infection 377
IFN-γ PCV2-specific SC increased at 2 weeks after vaccination, reaching a peak 1 week 378 later, with a mean value of 120 IFN-γ SC/10 6 PBMC and remained at approximately the same mean 379 value until 9 weeks of age. In the same period, at 2-3 weeks after vaccination, the number of age had a body weight at least 25% lower than the mean body weight of the respective treatment 424 group was 6.5% and 2.6% in placebo/control and vaccinated groups, respectively. 425
Vaccination reduced the overall mortality at both farms; the statistically significant 426 differences were related to a decreased number of pigs suffering from PMWS and showing specific 427 lesions in target tissues. In fact, only 1 of 408 vaccinated pigs died from PMWS. The results show 428 that the probability of a pig vaccinated with a single dose of Porcilis ® PCV at 3 weeks of age dying 429 from PMWS was 12 times less than that of an unvaccinated control pig. Furthermore, the similar an ELISA titres >6 log 2 . Conversely, in placebo/control pigs, either with MDAs <8 log 2 at inclusion 461 or with high levels (>8 log 2 ), a gradually declining course was detected and reached low levels 462 within a few weeks. At the time of late infection, occurring under the conditions of this study, none 463 of the controls was protected as demonstrated by the high proportion of viremic pigs (100% and 464 95%, respectively, from farm 1 and 2) and by the incidence of clinical signs and mortality. 465
Using the conditions of this study, we suggest that it is possible to set two different 466 thresholds of ELISA antibodies. When the titre of MDA is >8 log 2, detected in approximately 10% 467 of pigs, seroconversion to vaccination does not occur. Nevertheless, these animals, when infection 468 occured, had ELISA titres >6 log 2 thus resulting protected. Conversely, in controls, the highest 469 titres of MDA decline similarly so that, at later exposure to PCV2, the ELISA titres are <6 log 2 and 470 the animals are completely susceptible to infection with a high viral load. proteins. The intensity of the generated response differs using either the Cap protein or the whole 516 PCV as an in vitro stimulus; IFN-γ responses obtained by stimulating PBMC with the whole virus 517 are higher than with the Cap protein, suggesting that infected animals in which PCV2 is replicating 518 might respond strongly to other viral components different from the Cap protein (Fort et al., 2009b) . 519
Under the conditions of this study, we cannot exclude that coinfections had a role in modulating the 520 interaction of PCV2 and the adaptive immunity with effects on viral replication and load in vivo and 521 on the onset of the clinical abnormalities. 522
Based on these observations it seems that the development of the PCV2-specific cell-523 mediated response might help avoid progression of PCV2 infection even if further studies are 524 required to elucidate the inner mechanisms used by cell-mediated immunity to complete viral 525 clearance and its major antigenic target proteins. 526
In conclusion, the present study demonstrates the beneficial effect of vaccination with a 527 single dose of a PCV2 Cap vaccine against PCVD under field conditions. The vaccination reduces 
